Low fibrinogen level: A predisposing factor for venous thromboembolic events with hormone replacement therapy

Maura K. Whiteman, Yadong Cui, Jodi A. Flaws, Mark Espeland, Trudy L. Bush

Research output: Contribution to journalArticle

Abstract

Several studies have reported an association between hormone replacement therapy (HRT) in postmenopausal women and increased risk of idiopathic venous thromboembolic events (VTEs). Given the widespread use of HRT, it is important to identify factors that may predispose women on HRT to VTEs. To address this concern, we examined potential risk factors for VTEs in women assigned to HRT in the Postmenopausal Estrogen/Progestin Interventions (PEPI) study, a three-year, double-blinded, placebo-controlled trial of 875 postmenopausal women designed to assess the effects of HRT on heart disease risk factors (HDL cholesterol, fibrinogen, blood pressure, and insulin). Women with a history of estrogen-associated VTEs were excluded from the trial. Ten women, all assigned to HRT, had a VTE during PEPI. Only baseline fibrinogen varied significantly between those who did (mean = 249.0 mg/dl) and did not (mean = 280.8 mg/dl) have a VTE while assigned to HRT (P <0.03). Adjusting for covariates including age, smoking, body mass index, lipid levels, blood pressure, alcohol, exercise, and prior HRT or oral contraceptive use did not affect this finding. The significantly lower fibrinogen levels seen among women subsequently reporting VTEs may be a marker for a specific, but as yet undefined, coagulopathy that is magnified in the presence of exogenous hormones. However, larger studies are needed to confirm this finding.

Original languageEnglish (US)
Pages (from-to)271-273
Number of pages3
JournalAmerican Journal of Hematology
Volume61
Issue number4
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Hormone Replacement Therapy
Causality
Fibrinogen
Estrogens
Estrogen Replacement Therapy
Progestins
Blood Pressure
Oral Contraceptives
HDL Cholesterol
Heart Diseases
Body Mass Index
Smoking
Placebos
Alcohols
Hormones
Exercise
Insulin
Lipids

Keywords

  • Fibrinogen
  • Hormone replacement
  • Venous thrombosis

ASJC Scopus subject areas

  • Hematology

Cite this

Low fibrinogen level : A predisposing factor for venous thromboembolic events with hormone replacement therapy. / Whiteman, Maura K.; Cui, Yadong; Flaws, Jodi A.; Espeland, Mark; Bush, Trudy L.

In: American Journal of Hematology, Vol. 61, No. 4, 1999, p. 271-273.

Research output: Contribution to journalArticle

Whiteman, Maura K. ; Cui, Yadong ; Flaws, Jodi A. ; Espeland, Mark ; Bush, Trudy L. / Low fibrinogen level : A predisposing factor for venous thromboembolic events with hormone replacement therapy. In: American Journal of Hematology. 1999 ; Vol. 61, No. 4. pp. 271-273.
@article{078d4ba66e0c44629b479e2de8e577c0,
title = "Low fibrinogen level: A predisposing factor for venous thromboembolic events with hormone replacement therapy",
abstract = "Several studies have reported an association between hormone replacement therapy (HRT) in postmenopausal women and increased risk of idiopathic venous thromboembolic events (VTEs). Given the widespread use of HRT, it is important to identify factors that may predispose women on HRT to VTEs. To address this concern, we examined potential risk factors for VTEs in women assigned to HRT in the Postmenopausal Estrogen/Progestin Interventions (PEPI) study, a three-year, double-blinded, placebo-controlled trial of 875 postmenopausal women designed to assess the effects of HRT on heart disease risk factors (HDL cholesterol, fibrinogen, blood pressure, and insulin). Women with a history of estrogen-associated VTEs were excluded from the trial. Ten women, all assigned to HRT, had a VTE during PEPI. Only baseline fibrinogen varied significantly between those who did (mean = 249.0 mg/dl) and did not (mean = 280.8 mg/dl) have a VTE while assigned to HRT (P <0.03). Adjusting for covariates including age, smoking, body mass index, lipid levels, blood pressure, alcohol, exercise, and prior HRT or oral contraceptive use did not affect this finding. The significantly lower fibrinogen levels seen among women subsequently reporting VTEs may be a marker for a specific, but as yet undefined, coagulopathy that is magnified in the presence of exogenous hormones. However, larger studies are needed to confirm this finding.",
keywords = "Fibrinogen, Hormone replacement, Venous thrombosis",
author = "Whiteman, {Maura K.} and Yadong Cui and Flaws, {Jodi A.} and Mark Espeland and Bush, {Trudy L.}",
year = "1999",
doi = "10.1002/(SICI)1096-8652(199908)61:4<271::AID-AJH10>3.0.CO;2-0",
language = "English (US)",
volume = "61",
pages = "271--273",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Low fibrinogen level

T2 - A predisposing factor for venous thromboembolic events with hormone replacement therapy

AU - Whiteman, Maura K.

AU - Cui, Yadong

AU - Flaws, Jodi A.

AU - Espeland, Mark

AU - Bush, Trudy L.

PY - 1999

Y1 - 1999

N2 - Several studies have reported an association between hormone replacement therapy (HRT) in postmenopausal women and increased risk of idiopathic venous thromboembolic events (VTEs). Given the widespread use of HRT, it is important to identify factors that may predispose women on HRT to VTEs. To address this concern, we examined potential risk factors for VTEs in women assigned to HRT in the Postmenopausal Estrogen/Progestin Interventions (PEPI) study, a three-year, double-blinded, placebo-controlled trial of 875 postmenopausal women designed to assess the effects of HRT on heart disease risk factors (HDL cholesterol, fibrinogen, blood pressure, and insulin). Women with a history of estrogen-associated VTEs were excluded from the trial. Ten women, all assigned to HRT, had a VTE during PEPI. Only baseline fibrinogen varied significantly between those who did (mean = 249.0 mg/dl) and did not (mean = 280.8 mg/dl) have a VTE while assigned to HRT (P <0.03). Adjusting for covariates including age, smoking, body mass index, lipid levels, blood pressure, alcohol, exercise, and prior HRT or oral contraceptive use did not affect this finding. The significantly lower fibrinogen levels seen among women subsequently reporting VTEs may be a marker for a specific, but as yet undefined, coagulopathy that is magnified in the presence of exogenous hormones. However, larger studies are needed to confirm this finding.

AB - Several studies have reported an association between hormone replacement therapy (HRT) in postmenopausal women and increased risk of idiopathic venous thromboembolic events (VTEs). Given the widespread use of HRT, it is important to identify factors that may predispose women on HRT to VTEs. To address this concern, we examined potential risk factors for VTEs in women assigned to HRT in the Postmenopausal Estrogen/Progestin Interventions (PEPI) study, a three-year, double-blinded, placebo-controlled trial of 875 postmenopausal women designed to assess the effects of HRT on heart disease risk factors (HDL cholesterol, fibrinogen, blood pressure, and insulin). Women with a history of estrogen-associated VTEs were excluded from the trial. Ten women, all assigned to HRT, had a VTE during PEPI. Only baseline fibrinogen varied significantly between those who did (mean = 249.0 mg/dl) and did not (mean = 280.8 mg/dl) have a VTE while assigned to HRT (P <0.03). Adjusting for covariates including age, smoking, body mass index, lipid levels, blood pressure, alcohol, exercise, and prior HRT or oral contraceptive use did not affect this finding. The significantly lower fibrinogen levels seen among women subsequently reporting VTEs may be a marker for a specific, but as yet undefined, coagulopathy that is magnified in the presence of exogenous hormones. However, larger studies are needed to confirm this finding.

KW - Fibrinogen

KW - Hormone replacement

KW - Venous thrombosis

UR - http://www.scopus.com/inward/record.url?scp=0032818793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032818793&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1096-8652(199908)61:4<271::AID-AJH10>3.0.CO;2-0

DO - 10.1002/(SICI)1096-8652(199908)61:4<271::AID-AJH10>3.0.CO;2-0

M3 - Article

C2 - 10440916

AN - SCOPUS:0032818793

VL - 61

SP - 271

EP - 273

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 4

ER -